On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...